Humana boosts 2023 expectations for Medicare Advantage growth
The payer raised its guidance for earnings and revenue after beating Wall Street expectations on both metrics in the first quarter.
The payer raised its guidance for earnings and revenue after beating Wall Street expectations on both metrics in the first quarter.
Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.
Surgical cases at the operator’s ambulatory unit climbed 8% year over year, leading to a surge in ambulatory operating revenue.
The payer beat Wall Street expectations in the first quarter on both earnings and revenue, which reached $39 billion.
The ad spot comes as Congress heightens scrutiny of pharmacy benefit managers, drug purchasing middlemen that are often owned by health insurance companies.
The move comes as LCMC Health and the Federal Trade Commission file dueling court requests over whether state acquisition approval can preempt federal antitrust review of LCMC’s acquisition of three facilities from HCA Healthcare.
So far, the Department of Justice has charged 53 defendants and convicted 20 in healthcare-related COVID-19 schemes.
The operator logged an increase in admissions and a decrease in contract labor costs during the first quarter this year.
The stay suspends an order by a Texas judge that had invalidated the FDA’s approval of mifepristone, allowing access to continue while a circuit court hears the case.
With the right payment integrity approach and finely tuned focus, payers will find the exceptional service execution required to thrive in today’s environment.